decisionhealth Newsletters, Coder Pink Sheets - 2016 Issue 1 (January)
New coding guidance: Medicare releases new codes, payments for drug screens; watch for more on QW
Subscribe or sign in to view the full article.
Article Overview
This article covers Medicare’s updated drug screen coding framework for 2016, including the shift to new code structures, payment-related changes, and related laboratory billing considerations. It also discusses how the changes may affect presumptive and definitive testing, what to monitor regarding modifier guidance, and why private payer policies remain important for claim submission planning. The content is aimed at coders, lab staff, and revenue cycle personnel who work with drug testing claims.
Why This Topic Matters
Drug testing claims can be affected by code-set changes, payment adjustments, modifier reporting guidance, and payer-specific policies. Reviewing these updates helps practices and laboratories prepare for billing changes and reduce avoidable denials when coverage rules differ across payers.
Article Sections
-
Preparing for Medicare’s 2016 drug screen changes
Introduces the scope of the Medicare updates and the need for practices and labs to review ordering and billing workflows before filing claims.
-
Presumptive testing code changes and payment impact
Describes the revised structure for presumptive drug screen reporting and discusses associated payment changes and bundled components.
-
Modifier QW guidance
Summarizes the article’s discussion of Medicare’s reported modifier guidance and the need for clarification from the agency.
-
Definitive testing is class-based
Explains the article’s discussion of definitive drug testing at a broad level and how the topic is framed within Medicare coding.
-
Watch your private payers
Covers the need to verify payer-specific preferences and policy differences for drug screen claims across commercial insurers.
What You Will Learn
- How Medicare’s drug screen coding changes are organized for 2016
- What payment and billing issues are associated with the updated drug testing framework
- Why modifier reporting and payer-specific rules require attention
- How the article frames presumptive versus definitive drug testing
- What to monitor when coordinating claims with private payers
Who Should Read This
- Medical coders
- Laboratory staff
- Billing staff
- Revenue cycle personnel
- Pain management practices
- Physician office staff
Codes Discussed
Code Ranges Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com